Dr. Maurie Markman comments on a study published in the Journal of Clinical Oncology describing the use of the EML4-ALK fusion oncogene to predict response to EGFR therapy in patients with NSCLC. Medscape Genomic Medicine
The PARAMOUNT trial answers an important question: Is there a role for continuation of maintenance pemetrexed for patients with NSCLC? Dr. Mark Kris comments on the findings of this important study. br / iMedscape Hematology-Oncology/i
A new study finds a clear survival benefit with radical prostatectomy vs watchful waiting, but only in men younger than 65. Dr. Gerald Chodak reviews the data. Medscape Urology
Metastatic breast cancer first-line treatments with varying dosing frequencies are compared for efficacy and toxicity. Is one regimen superior? Clinical Breast Cancer
This paper explains the sex differences in lung cancer, including differences in molecular abnormalities, growth factor receptors, hormonal influences, as well as variations in treatment outcomes. Expert Review of Respiratory Medicine
